

STYPTOVIT E

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
abbreviated prescribing information for STYPTOVIT E (Etamsylate Tablets 500mg)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Etamsylate is a synthetic antihaemorrhagic and angioprotective drug acting on the first step of haemostasis (endothelium-platelet interaction). By improving platelet adhesiveness and restoring capillary resistance, it is able to reduce bleeding time and blood losses. Etamsylate has no vasoconstrictor action, it does not influence fibrinolysis nor modify the plasma coagulation factors.

INDICATION: Styptovit E tablets are indicated for the treatment of small vessel haemorrhage menorrhagia (including IUD users) prophylaxis of periventricular haemorrhage in neonates.

DOSAGE AND ADMINISTRATION: Styptovit E uncoated Etamsylate tablet should be taken as directed by Physician.

CONTRAINDICATION: Acute porphyria. Hypersensitivity to the active substance or to any of the excipients. Bronchial asthma, proven hypersensitivity to sulphites.

WARNINGS & PRECAUTIONS: If Styptovit E is administered for a reduction of excessive and/or prolonged menstrual haemorrhages, and no improvement is observed, possible pathological causes should be looked for and excluded.

DRUG INTERACTIONS: No interaction is known up to now.

ADVERSE REACTIONS: Gastralgia, diarrhea, nausea, headache, skin rash. The allergic reactions may lead to anaphylactic shock and cause life-threatening asthma attacks.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

IN/ STYPTOVIT E 500 mg/JUN-22/01/ABPI

(Additional information is available on request)